In a report published Friday, Deutsche Bank analyst Alethia Young reiterated a Buy rating on Alnylam Pharmaceuticals ALNY, and raised the price target from $40.00 to $60.00.
In the report, Deutsche Bank noted, “After R&D day and subQ top-line data, we are more confident that subQ dosing is a platform game changer and believe delivery technology is de-risked. The subQ dose allows the company to pursue many therapeutic targets in high unmet need areas. Maintain Buy.”
Alnylam Pharmaceuticals closed on Thursday at $43.53.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in